A study published in the World Journal of Surgical Oncology examining the prevalence, risk factors, and prognostic value of chemotherapy-associated venous thromboembolism (VTE) in patients with ovarian cancer found a pooled prevalence of 9% (95% CI, 0.06–0.12) for this group of patients.
The data also found substantial risk factors for chemotherapy-related VTE, potentially assisting future efforts to target preventative measures in patients with this disease.
“Our findings revealed that the pooled prevalence of chemotherapy-related VTE in OC was approximately 9% in [ovarian cancer] with substantial heterogeneity (88.9%),” wrote the investigators. “Considering that significant heterogeneity may impair the evidence quality of the pooled estimate, the meta-regressions based on publication time, sample size, and [Newcastle-Ottawa Scale] score were performed to explore the potential…
